檢索結果 - Ramalingam, Suresh

Personalized therapy for lung cancer: striking a moving target 由 Pakkala, Suchita, Ramalingam, Suresh S.

獲取全文 獲取全文 獲取全文

Inhibition of insulin-like growth factor receptor: end of a targeted therapy? 由 Pillai, Rathi N., Ramalingam, Suresh S.

獲取全文 獲取全文 獲取全文

Necitumumab: a new therapeutic option for squamous cell lung cancer? 由 Pillai, Rathi N., Ramalingam, Suresh S.

獲取全文 獲取全文 獲取全文

Second-Generation ALK Inhibitors: Filling the Non “MET” Gap 由 Ramalingam, Suresh S., Khuri, Fadlo R.

獲取全文 獲取全文 獲取全文

Targeting EGFR in lung cancer: Lessons learned and future perspectives 由 Steuer, Conor E., Ramalingam, Suresh S.

獲取全文 獲取全文 獲取全文

Immunotherapy in previously treated non-small cell lung cancer (NSCLC) 由 Leal, Ticiana A., Ramalingam, Suresh S.

獲取全文 獲取全文 獲取全文

Improving outcomes for brain metastases in EGFR mutated NSCLC 由 Carlisle, Jennifer W., Ramalingam, Suresh S.

獲取全文 獲取全文 獲取全文

Reply to N. Hanna et al and L. Xie et al 由 Ramalingam, Suresh S., Dahlberg, Suzanne E.

獲取全文 獲取全文 獲取全文

EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic? 由 Steuer, Conor E., Ramalingam, Suresh S.

獲取全文 獲取全文 獲取全文

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC 由 Osta, Badi El, Ramalingam, Suresh S.

獲取全文 獲取全文 獲取全文

Gene Expression Profiling of Non-Small Cell Lung Cancer 由 Singhal, Sunil, Miller, Daniel, Ramalingam, Suresh, Sun, Shi-Yong

獲取全文 獲取全文 獲取全文

Targeting KRAS-Mutant Non–Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations 由 Burns, Timothy F., Borghaei, Hossein, Ramalingam, Suresh S., Mok, Tony S., Peters, Solange

獲取全文 獲取全文 獲取全文

Retinoic acid enhances TRAIL induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression 由 Dhandapani, Latha, Yue, Ping, Ramalingam, Suresh S., Khuri, Fadlo R., Sun, Shi-Yong

獲取全文 獲取全文 獲取全文

Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib 由 Chen, Zhen, Yu, Danlei, Owonikoko, Taofeek K., Ramalingam, Suresh S., Sun, Shi-Yong

獲取全文 獲取全文 獲取全文

What is the role of maintenance therapy in the treatment of non-small cell lung cancer? 由 Jiang, Yixing, Owonikoko, Taofeek K., Ramalingam, Suresh S., Khuri, Fadlo R., Belani, Chandra P.

獲取全文 獲取全文 獲取全文

Phosphorylated Eukaryotic Translation Initiation Factor 4 (eIF4E) is Elevated in Human Cancer Tissues 由 Fan, Songqing, Ramalingam, Suresh S., Kauh, John, Xu, Zhiheng, Khuri, Fadlo R., Sun, Shi-Yong

獲取全文 獲取全文

Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury 由 Rice, Shawn J., Hyland, Victoria, Behera, Madhusmita, Ramalingam, Suresh S., Bunn, Paul, Belani, Chandra P.

獲取全文 獲取全文 獲取全文

The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition 由 Chen, Zhen, Vallega, Karin A., Chen, Haiying, Zhou, Jia, Ramalingam, Suresh S., Sun, Shi-Yong

獲取全文 獲取全文 獲取全文

Bevacizumab’s Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgical... 由 Varlotto, John M., Wang, Yating, Sun, Zhuoxin, Wakelee, Heather A., Ramalingam, Suresh, Schiller, Joan

獲取全文 獲取全文 獲取全文

Diallyl Trisulfide Selectively Causes Bax and Bak Mediated Apoptosis in Human Lung Cancer Cells 由 Xiao, Dong, Zeng, Yan, Hahm, Eun-Ryeong, Kim, Young-Ae, Ramalingam, Suresh, Singh, Shivendra V.

獲取全文 獲取全文 獲取全文